Relapsing Remitting Multiple Sclerosis
The biannual infusion is approved for the treatment of adults with relapsing and progressive forms of multiple sclerosis.
Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.
Previous MRI studies focused on gray matter changes only.
The authors aimed to identify confirmed disability improvement (CDI), which reflects a clinically meaningful change in EDSS score.
Differences in gut bacteria were apparent between patients with active RRMS and those in remission.
The 2 mg dose appears to be most efficacious.
If approved, the monoclonal antibody will be the first treatment indicated for both RMS and PPMS.
The company said it will continue to explore its options.
Notably, results were achieved without maintenance therapy.
At follow-up, 22 patients were cognitively impaired compared to 34 at baseline.
The monthly injectable comes with a boxed warning for severe liver injury.
Treatment with the biannual injection consistently resulted in greater achievement of NEDA compared to standard care.
Women who experience relapse and take corticosteroids may be at risk for complications.
No differences were observed among the group who switched therapy and controls.
Combined results confirmed that intrathecal LCN2 production was increased in MS patients, especially those with SPMS and PPMS.
Natalizumab treatment linked to 15.9% increase of value in JC virus.
When first-line therapies fail, physicians must consider several factors when choosing the next course of treatment for their RRMS patients.
The results suggest that addressing depression may help improve other symptoms, like pain and fatigue.
MS clinical trials have triple the success rate of those focused on other diseases.
Neurology Advisor Articles
- OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms
- History of Migraine Associated With Higher Risk for Cochlear Disorders
- Patent Foramen Ovale Closure for Stroke Prevention: Key Principles for Clinical Practice
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- A Model for Predicting Quality of Life Improvements After Deep Brain Stimulation
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- FDA Grants Orphan Drug Status to Angelman Syndrome Treatment
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Clinical, Radiologic Markers Predictive of Cortical Superficial Siderosis in ICH Identified
- Migraine Pain Location May Not Have Clinical Implications